Ditropan XL Related Published Studies
Well-designed clinical trials related to Ditropan XL (Oxybutynin)
A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin
vaginal ring for alleviation of overactive bladder symptoms in women. [2014]
Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized,
double-blind, placebo-controlled trial and an assessment of predictive factors. [2012]
Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. [2011.11]
Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (</= 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. [2011.02]
[Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder]. [2011.01]
Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. [2011.01]
Efficacy of oral extended-release oxybutynin in cognitively impaired older
nursing home residents with urge urinary incontinence: a randomized
placebo-controlled trial. [2011]
Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. [2010.07.06]
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. [2010.05]
Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. [2010]
Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. [2009.11]
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. [2009.10]
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. [2009.04]
Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. [2008.09]
Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. [2008.09]
Intravesical Oxybutynin for Children With Poorly Compliant Neurogenic Bladder: A Systematic Review. [2008.07.17]
Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. [2008.05]
A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. [2008.05]
Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. [2008.01]
The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin. [2008.01]
Clinical and urodynamic efficacy of oxybutynin and verapamil in the treatment of nocturnal enuresis after formation of orthotopic ileal neobladders. A prospective, randomized, crossover study. [2008]
Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. [2007.03]
Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. [2007.01]
Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. [2007.01]
The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. [2006.12]
Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. [2006.11]
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. [2006.09]
A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. [2006.03]
Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. [2006.03]
Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. [2006.02]
Comparison of effects of treatment of primary nocturnal enuresis with oxybutynin plus desmopressin, desmopressin alone or imipramine alone: a randomized controlled clinical trial. [2005.09]
Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. [2005.08]
Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. [2005.07]
Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. [2005.05]
Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. [2005.04.01]
Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. [2005]
Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. [2004.12]
Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. [2004.10]
Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. [2004.10]
A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. [2004.07]
A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. [2004.07]
Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin. [2004]
Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. [2003.11]
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. [2003.08]
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. [2003.06]
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. [2003.06]
Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. [2003.01]
Transdermal oxybutynin: for overactive bladder. [2003]
A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. [2002.09]
Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. [2002.08]
Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. [2002.05]
Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. [2002.02]
Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). [2002]
Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. [2001.10]
Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. [2001.07]
A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability. [2001.07]
A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. [2001.07]
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. [2001.06]
A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. [2001.05]
Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. [2001.05]
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. [2001.04]
Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation. [2001.02]
Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. [2001.02]
Interstitial cystitis: bladder training with intravesical oxybutynin. [2000.06]
Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. [2000.05]
A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. [2000.05]
[Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women] [2000.04]
Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial. [2000.03]
Combination therapy of imipramine with oxybutynin in children with enuresis nocturna. [2000]
A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. [1999.10]
Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. [1999.06]
Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. [1999.06]
Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. [1999.03]
Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. [1999]
Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. [1998.06]
[Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test] [1998.05]
Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. [1998.01]
Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet. [1997.07]
Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. [1997]
Nocturnal enuresis and daytime wetting: a multicentric trial with oxybutynin and desmopressin. [1997]
Efficacy of oxybutynin, pseudoephedrine and indomethacin in the treatment of primary nocturnal enuresis. [1996.04]
Anticholinergic medication for the unstable bladder: prospective trials of imipramine/propantheline versus penthienate and oxybutynin versus penthienate. [1996]
Effect of food on the bioavailability of oxybutynin from a controlled release tablet. [1996]
Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. [1995.07]
Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. [1995.06]
[Topical administration of oxybutynin hydrochloride in women with urge incontinence. Results of a prospective randomized double-blind study] [1995.05]
Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. [1995.04]
[Topical use of oxybutynin hydrochloride in women with urge incontinence] [1994]
Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. [1991.04]
Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. [1990.11]
The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. [1990.06]
Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. [1989.05]
Oxybutynin efficacy in the treatment of primary enuresis. [1988.07]
Well-designed clinical trials possibly related to Ditropan XL (Oxybutynin)
Which anticholinergic drug for overactive bladder symptoms in adults. [2012]
Behavioral Versus Drug Treatment for Overactive Bladder in Men: The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. [2011.11.07]
Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? [2011.07]
Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder. [2011.05]
Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women. [2010.08]
Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. [2010.01]
Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. [2009.11]
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. [2009.10.07]
|
